Two levers that change what a drug costs without changing what the patient receives. They are the most defensible savings available.
Most drug cost management involves a tradeoff, asking someone to accept a different product or a delay. Two levers do not: moving where a drug is administered, and substituting a product that is therapeutically equivalent by regulatory determination.
Site of care
An infused drug administered in a hospital outpatient department, a physician office, an infusion suite, or the patient’s home is the same drug. What differs is the facility payment attached to it.
The commercial course documented the general pattern: outpatient hospital facility services averaged 279 percent of Medicare while ambulatory surgery centers averaged 170 percent. Administered drugs sit inside that same structure, with the facility component varying by setting.
The conditions for moving a patient are clinical and specific:
- The therapy must be safe to administer in the lower-acuity setting, which depends on the drug’s reaction profile and the patient’s history.
- The patient must be stable on it, so first doses generally stay in higher-acuity settings.
- The infrastructure must exist, meaning a physician office with infusion capacity or a home infusion provider.
Where those hold, the savings require nothing from the patient except a different address, and often improve their experience.
Biosimilar and generic substitution
Generic substitution is routine and largely automated. Biosimilars are the harder case and the larger opportunity, because biologics carry the highest costs in the specialty category.
The barriers are practical rather than clinical: prescriber familiarity, patient concern about switching a working therapy, and the fact that formulary placement can favor a higher-list-price originator whose rebates make it cheaper on a net basis. That last point connects directly to the next lesson.
Where the resistance actually comes from
Both levers face opposition that is worth understanding rather than dismissing:
| Objection | How much weight it deserves |
|---|---|
| The hospital setting is safer for reactions | Real for first doses and high-risk agents, weaker for stable patients on well-tolerated therapy |
| Hospital margin on administered drugs funds other services | True, and it is a claim about cross-subsidy, not about the value of the infusion |
| Switching a stable patient’s biologic risks destabilization | Real for a minority of agents and patients, and often generalized well beyond that |
| The originator is cheaper net of rebates | Sometimes true and checkable, which is the point |
Worth remembering: the second row deserves an honest hearing rather than dismissal. Hospital margin on administered drugs does subsidize services that lose money, including emergency care and behavioral health. Moving infusions out of hospital outpatient departments is a real savings for the payer and a real revenue loss for institutions whose other services depend on it. That does not make it wrong, and it does mean the savings are not free at the system level. Anyone advancing a site-of-care strategy should know they are shifting a cross-subsidy, and should be able to say so when a hospital raises it.
Key takeaways
- Site of care changes the facility payment attached to an identical therapy.
- Movement requires clinical suitability, patient stability, and available infrastructure.
- Biosimilar substitution is limited by familiarity, switching concerns, and rebate-driven formulary placement.
- Hospital margin on administered drugs cross-subsidizes other services, which is a real consideration rather than an excuse.
Sources
Check your understanding
Why is site of care a particularly defensible cost lever for administered drugs?
Nothing about the therapy changes. Hospital outpatient facility prices averaged 279 percent of Medicare against 170 percent at ambulatory surgery centers, and administered drugs follow the same pattern.